Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China flag China · Delayed Price · Currency is CNY
26.84
+1.22 (4.76%)
At close: Mar 6, 2026

SHA:688443 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
230.7230.071.070.48-
Other Revenue
-0.030.15-39.19
230.7230.091.210.4839.19
Revenue Growth (YoY)
666.65%2384.11%154.92%-98.79%3502.99%
Cost of Revenue
-5.92-0.241.7719.67
Gross Profit
230.7224.171.45-1.319.52
Selling, General & Admin
-252.49173.79153.6224.22
Research & Development
-609.79620.4454.49295.32
Other Operating Expenses
760.023.272.561.31.84
Operating Expenses
760.02866.19796.74609.42321.34
Operating Income
-529.3-842.02-795.29-610.72-301.82
Interest Expense
--28.9-34.99-32.75-32.42
Interest & Investment Income
-66.7517.460.880.43
Currency Exchange Gain (Loss)
---0.1-0.80.24
Other Non Operating Income (Expenses)
-6.92-0.02-0.02-0.01-0.02
EBT Excluding Unusual Items
-536.22-804.18-812.94-643.39-333.59
Gain (Loss) on Sale of Investments
-2.581.947.144.11
Gain (Loss) on Sale of Assets
--0.54-0-0-
Asset Writedown
-----0.43
Other Unusual Items
-4.869.6859.897.78
Pretax Income
-536.22-797.27-801.32-576.37-322.13
Net Income
-536.22-797.27-801.32-576.37-322.13
Net Income to Common
-536.22-797.27-801.32-576.37-322.13
Shares Outstanding (Basic)
365367321274275
Shares Outstanding (Diluted)
365367321274275
Shares Change (YoY)
-0.72%14.63%16.79%-0.32%-
EPS (Basic)
-1.47-2.17-2.50-2.10-1.17
EPS (Diluted)
-1.47-2.17-2.50-2.10-1.17
Free Cash Flow
--620.75-468.56-323.85-350.52
Free Cash Flow Per Share
--1.69-1.46-1.18-1.27
Gross Margin
100.00%80.32%119.44%-273.11%49.80%
Operating Margin
-229.41%-2797.87%-65645.33%-128506.77%-770.14%
Profit Margin
-232.41%-2649.19%-66142.68%-121278.86%-821.97%
Free Cash Flow Margin
--2062.65%-38675.98%-68143.75%-894.41%
EBITDA
-474.18-786.89-746.46-570.86-270.57
EBITDA Margin
-205.52%----
D&A For EBITDA
55.1255.1248.8439.8631.26
EBIT
-529.3-842.02-795.29-610.72-301.82
EBIT Margin
-229.41%----
Revenue as Reported
-30.091.210.4839.19
Advertising Expenses
-2.340.35--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.